Status | Study |
Completed |
Study Name: Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Condition: Glaucoma Date: 2013-06-18 Interventions: Device: Silicone plate Ahmed Glaucoma Valve (Model FP7) |
Completed |
Study Name: Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma Condition: Neovascular Glaucoma Date: 2012-10-18 Interventions: Drug: Aflibercept Details covered in arm description |
Completed |
Study Name: Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma Condition: Neovascular Glaucoma Rubeosis Date: 2011-05-27 Interventions: Drug: 0.5mg intraocular Ranibizumab (Lucentis) short- and long-term effects of 0.5mg intraocular Ranibiz |
Terminated |
Study Name: Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube Condition: Primary Open Angle Glaucoma Primary Angle Closure Glaucoma Date: 2011-02-22 Interventions: Procedure: Molteno 3 glaucoma drainage shunt Patients needing glaucoma drainage surgery |
Completed |
Study Name: Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma Condition: Refractory Glaucoma Date: 2010-05-21 Interventions: Drug: Subconjunctival Avastin |
Completed |
Study Name: Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma Condition: Neovascular Glaucoma Date: 2010-01-07 Interventions: Procedure: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin The operative |
Completed |
Study Name: Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? Condition: Glaucoma Date: 2009-02-27 Interventions: Drug: Triesence At the end of |
Completed |
Study Name: Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Condition: Choroidal Melanoma Date: 2008-10-02 Interventions: Drug: ranibizumab Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of |
Withdrawn |
Study Name: Lucentis for New Onset Neovascular Glaucoma Condition: Glaucoma New Onset Glaucoma Neovascu Date: 2008-07-29 Interventions: Drug: Ranibizumab (Lucentis) 0.5 mg ranibizumab intravitreal injection single dose administration |
Completed |
Study Name: Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Condition: Glaucoma Rubeosis Iridis Date: 2007-11-08 Interventions: Drug: bevacizumab 1.25mg/month |